Gerhardt Attard focuses on DNA Plasma-based biomarkers in advanced prostate cancer (16 minute presentation). He presents the rationale for using plasma DNA. Plasma collection is routine and are adding to the registries allows for ongoing clinical trials. Circulating tumor DNA is detected in plasma from ALL progressing mCRPC patients. Plasma DNA is representative of clinically relevant progressing metastases. Plasma DNA could be used to select targeted treatment - however we now need prospective clinical trials to evaluate this approach prior to changing clinical management of mCRPC patients.